Daratumumab, lenalidomide and dexamethasone in newly diagnosed systemic light chain amyloidosis patients associated with multiple myeloma

被引：2
|
作者：
Kawano, Yawara [1 ,2 ]
Hata, Hiroyuki [3 ]
Takashio, Seiji [2 ,4 ]
Tsujita, Kenichi [4 ]
Ueda, Mitsuharu [2 ,5 ]
Matsuoka, Masao [1 ]
机构：
[1] Kumamoto Univ, Grad Sch Med Sci, Dept Hematol Rheumatol & Infect Dis, Kumamoto, Japan
[2] Kumamoto Univ Hosp, Amyloidosis Ctr, Kumamoto, Japan
[3] Kumamoto Univ, Div Informat Clin Sci, Fac Med Sci, Kumamoto, Japan
[4] Kumamoto Univ, Grad Sch Med Sci, Dept Cardiovasc Med, Kumamoto, Japan
[5] Kumamoto Univ, Grad Sch Med Sci, Dept Neurol, Kumamoto, Japan
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2022年 / 198卷 / 03期
关键词：
CARDIAC BIOMARKERS; AL AMYLOIDOSIS; CRITERIA;
D O I：
10.1111/bjh.18234
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E38 / E41
页数：4
相关论文
共 50 条
  • [1] Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma
    Kumar, Shaji K.
    Kapoor, Prashant
    Laplant, Betsy
    Phuong-Dung, Liang
    Muchtar, Eli
    Buadi, Francis K.
    Gonsalves, Wilson I.
    Malave, Gabriella C.
    Vossen, Alanna M.
    Dingli, David
    Go, Ronald S.
    Warsame, Rahma M.
    Kourelis, Taxiarchis
    Hwa, Yi L.
    Fonder, Amie
    Hobbs, Miriam A.
    Lust, John A.
    Lacy, Martha Q.
    Dispenzieri, Angela
    Hayman, Suzanne R.
    Leung, Nelson
    Rajkumar, S. Vincent
    Gertz, Morie A.
    [J]. BLOOD, 2020, 136
  • [2] Bortezomib with Dexamethasone in Newly Diagnosed Patients with Primary Systemic Light Chain Amyloidosis or Multiple Myeloma-Associated AL Amyloidosis
    Huang, Beihui
    Li, Juan
    Liu, Junru
    Zheng, Dong
    Chen, Mei
    Zhou, Zhenhai
    Xu, Duorong
    Zou, Waiyi
    [J]. BLOOD, 2012, 120 (21)
  • [3] Daratumumab Plus Bortezomib and Dexamethasone in Newly Diagnosed Systemic Light Chain Amyloidosis
    Kennedy, Vanessa E.
    Natsuhara, Kelsey
    Shah, Nina D.
    Arora, Shagun
    Wolf, Jeffrey
    Martin, Thomas G.
    Aras, Mandar A.
    Chung, Alfred
    Wong, Sandy W.
    [J]. CURRENT PROBLEMS IN CANCER, 2023, 47 (03)
  • [4] Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
    Jakubowiak, Andrzej
    Usmani, Saad Z.
    Krishnan, Amrita
    Lonial, Sagar
    Comenzo, Raymond L.
    Wang, Jianping
    de Boer, Carla
    Deraedt, William
    Weiss, Brendan M.
    Schecter, Jordan M.
    Chari, Ajai
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (10): : 701 - 710
  • [5] Daratumumab: A Review in Newly Diagnosed Systemic Light Chain Amyloidosis
    Blair, Hannah A.
    [J]. DRUGS, 2022, 82 (06) : 683 - 690
  • [6] Daratumumab: A Review in Newly Diagnosed Systemic Light Chain Amyloidosis
    Hannah A. Blair
    [J]. Drugs, 2022, 82 : 683 - 690
  • [7] Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) and Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (DKRd) As Induction Therapy in Newly Diagnosed Multiple Myeloma
    Tan, Carlyn
    Maclachlan, Kylee H.
    Nemirovsky, David
    Derkach, Andriy
    Hultcrantz, Malin
    Hassoun, Hani
    Mailankody, Sham
    Shah, Urvi A.
    Rajeeve, Sridevi
    Patel, Dhwani
    Shekarkhand, Tala
    Rueda, Colin
    Lahoud, Oscar Boutros
    Shah, Gunjan L.
    Scordo, Michael
    Chung, David
    Landau, Heather
    Giralt, Sergio A.
    Lesokhin, Alexander
    Usmani, Saad Z.
    [J]. BLOOD, 2023, 142
  • [8] Phase 2 Trial of Ixazomib, Lenalidomide, Dexamethasone and Daratumumab in Patients with Newly Diagnosed Multiple Myeloma
    Kumar, Shaji K.
    Kapoor, Prashant
    Laplant, Betsy
    Muchtar, Eli
    Buadi, Francis K.
    Gonsalves, Wilson I.
    Dingli, David
    Go, Ronald S.
    Warsame, Rahma
    Kourelis, Taxiarchis
    Lust, John A.
    Lacy, Martha Q.
    Dispenzieri, Angela
    Hayman, Suzanne R.
    Hwa, Yi
    Fonder, Amie
    Hobbs, Miriam
    Leung, Nelson
    Rajkumar, S. Vincent
    Gertz, Morie A.
    Wolfe, Eric
    [J]. BLOOD, 2018, 132
  • [9] A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis
    Cibeira, Maria T.
    Oriol, Albert
    Lahuerta, Juan J.
    Mateos, Maria-Victoria
    de la Rubia, Javier
    Hernandez, Miguel T.
    Granell, Miquel
    Fernandez de Larrea, Carlos
    San Miguel, Jesus F.
    Blade, Joan
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2015, 170 (06) : 804 - 813
  • [10] Daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) vs daratumumab, carfilzomib, lenalidomide and dexamethasone (DKRd) as induction therapy in newly diagnosed multiple myeloma
    Tan, Carlyn Rose
    Maclachlan, Kylee
    Nemirovsky, David
    Derkach, Andriy
    Hultcrantz, Malin
    Hassoun, Hani
    Mailankody, Sham
    Shah, Urvi
    Patel, Dhwani
    Shekarkhand, Tala
    Rueda, Colin
    Lahoud, Oscar
    Shah, Gunjan
    Scordo, Michael
    Chung, David
    Landau, Heather
    Giralt, Sergio
    Usmani, Saad
    Lesokhin, Alexander
    Korde, Neha
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S127 - S127
12345